Bactiguard recruits experienced Chief Marketing and Communications Officer

Petra Kaur Ljungman, with many years of experience from leading positions in the medical device and pharmaceutical industry, has been recruited for a newly established, global role as Chief Marketing and Communications Officer. She will take up her position in January 2021 and will report to the CEO.

“Petra Kaur Ljungman has a broad experience ranging from research to sales, business development, communications and marketing in both the pharmaceutical and medical device industries and the advertising industry. She is a driven marketing manager and communicator, who has successfully developed brand and digital strategies for several companies,” says Cecilia Edström, CEO.

“Petra's strategic ability and operational experience make her well suited for the new role in Bactiguard's management team. We need to advance our positions digitally to accelerate growth and it is with pleasure that I welcome Petra,” continues Cecilia Edström.

“I am very excited about joining Bactiguard, contributing to further expansion and increased influence of Bactiguard's brands. With new challenges due to the pandemic, it is more relevant than ever to increase focus on infection prevention  to both reverse the trend of increasing antibiotic resistance and reduce the spread of bacteria and viruses. To me this is particularly engaging – to be part of leveraging sustainable value to users and healthcare providers worldwide,” says Petra Kaur Ljungman.

Petra Kaur Ljungman has a Master of Science in biology from Umeå University and has done research at a doctoral level in pharmacology at Karolinska Institutet. She has extensive experience from leading roles within sales and marketing in pharmaceutical and medical device companies such as Astra Zeneca, Sanofi and from advertising agencies such as Ogilvy / INGO. Since 2014, she has been active within Brighter AB, initially as a board member and then in the management team responsible for marketing and communication.

Petra Kaur Ljungman will take up her position at the beginning of January 2021. The Bactiguard management team currently consists of Cecilia Edström, CEO; Gabriella Björknert Caracciolo, CFO; Stefan Grass, Chief Medical Officer and Sathish Subramaniam, Chief Operations Officer. Sathish Subramaniam took over his global role after the integration of Vigilenz. He was previously responsible for Bactiguard's operations in Malaysia.

Bactiguard advanced in 2020 to Allbright's green list of the stock exchange's most equal companies.
 

For further information, please contact:
Cecilia Edström, CEO, phone: +46 8 440 58 80

 

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. In this way, we save significant costs for healthcare and society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through license agreements and with our BIP (Bactiguard Infection Protection) portfolio of products. Through our license partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com

Tags:

About Us

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com